A researcher explains the rationale for and goals of her investigations of blood-based biomarkers for Alzheimer’s disease specifically in women.
Both a characteristic clinical syndrome and positive amyloid beta and tau markers are needed for reliable diagnosis, advise new recommendations from an international expert group.
A screening blood test could accelerate drug development and enable earlier, more effective intervention. We offer an overview of promising efforts in pursuit of a reliable blood-based biomarker.
A cohort analysis from the Professional Fighters Brain Health Study shows that tau levels rise over time with repeated head impacts. Longer follow-up may reveal whether that leads to long-term brain decline.